Le Lézard
Classified in: Health
Subject: FDA

Owlet Submits for FDA Clearance on Owlet Smart Sock


LEHI, Utah, Jan. 23, 2017 /PRNewswire/ -- Owlet Baby Care has submitted a 510(k) to the U.S. Food and Drug Administration (FDA), seeking clearance for a medical version of the Owlet Smart Sock. The application is now pending review. Owlet shared its third-party accuracy validation testing to the FDA as part of its application. 

Using technology called pulse oximetry, the Owlet Smart Sock is designed to send notifications to a Base Station and then via Wi-Fi to a parents' smartphone, if a baby's heart rate or oxygen fall outside a preset range. The Owlet is designed for infants up to 18 months old.

FDA clearance on a medical version of the Owlet Smart Sock could provide the opportunity to expand use into the medical space.

ABOUT OWLET BABY CARE
Owlet Baby Care was founded in 2013 by a team of passionate parents who wanted to bring themselves and other parents around the globe peace of mind and assurance by developing a monitor that tracks a baby's oxygen and heart rate. Using clinically proven technology called pulse oximetry, the Owlet Smart Sock is designed to send notifications to the Base Station and via Wi-Fi to a smartphone, if a baby's heart rate or oxygen fall outside a preset range.

 

SOURCE Owlet Baby Care, Inc.


These press releases may also interest you

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...



News published on and distributed by: